Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Canopy Growth CorporationNASDAQ: CGC

Gross Profit · Q4 FY2025 · quarter ended Mar 2026

Gross profit declines year over year

Q4 FY2025 gross profit of CA$8.26M fell 21.7% year over year, behind the -2.3% change in trailing-twelve-month gross profit. Sequentially, it fell 72.0% from the prior quarter.

Context

  • Gross profit amounted to 20.1% of revenue in FY2025, down 9.5 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -21.7% toward the trailing-twelve-month pace of -2.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$8.26M-72.0% QoQ
Last fiscal yearMar 2026
CA$97.16M+22.2% YoY
LTMMar 2026
CA$77.66M-2.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.7%——
1 year+22.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

CAD · from the income statement

Latest · FY2025
97.16M CAD
Year-over-year change
+22.2%

Gross Profit vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.3% is the 5th highest of 8, against a peer median of +38.3%.
  • Gross profit amounts to 24.9% of revenue for CGC, versus a peer median of 74.4%.
CGC Competitors
Gross Profit for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$360.13M USD+38.3%-10.2%99.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$176.08M CAD-6.1%+4.2%56.6%
DHDefinitive Healthcare Corp.LTM Mar 2026$172.84M USD-9.4%+0.6%72.5%
CGCCanopy Growth CorporationLTM Mar 2026CA$77.66M CAD-2.3%—24.9%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$42.13M USD—+1.0%31.2%
TKNOAlpha Teknova, Inc.LTM Mar 2026$13.93M USD+73.5%-8.4%33.3%
BIOABioAge Labs, Inc.LTM Mar 2026$10.25M USD+606.6%—99.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$6.39M USD+74.8%-31.4%76.3%
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD———
LYELLyell Immunopharma, Inc.LTM Mar 2026-$2.3M USD-3640.0%—7422.6%
Peer median (excluding CGC) —+38.3%-3.9%74.4%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue475.7M333.25M297.15M269M483.67M
Cost of Revenue663.11M396.78M216.26M189.48M386.51M
Gross Profit(187.41M)(63.53M)80.88M79.51M97.16M
Gross Margin-39.4%-19.1%27.2%29.6%20.1%
Research & Development32.26M21.72M4.61M1.91M0
Selling, General & Admin361.1M297.98M180.59M121.71M223.11M
Operating Expenses831.39M2.57B309.6M196.65M322.6M
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
EBITDA(52.98M)(2.88B)(312.83M)(479.31M)50.86M
EBITDA Margin-11.1%-864.2%-105.3%-178.2%10.5%
Operating Income(1.02B)(2.63B)(228.71M)(117.14M)(161.66M)
Operating Margin-214.2%-789.3%-77.0%-43.5%-33.4%
Interest Income6.6M24.28M16.24M8.82M10M
Interest Expense103.94M126.16M105.35M74.57M38.19M
Other Income / Expenses750.94M(455.64M)(242.64M)(479.85M)(101.23M)
Income Before Tax(267.86M)(3.09B)(471.36M)(597M)(262.89M)
Pre-Tax Margin-56.3%-926.1%-158.6%-221.9%-54.4%
Income Tax Expense(8.95M)(5.73M)12.33M7.14M23K
Net Income(310.04M)(3.28B)(657.27M)(598.12M)(366.64M)
Net Margin-65.2%-983.7%-221.2%-222.4%-75.8%
EPS (Basic)(7.70)(70.70)(6.47)(5.53)(0.88)
EPS (Diluted)(7.70)(70.70)(8.79)(5.53)(0.88)
Weighted Avg Shares39.13M46.37M101.63M107.55M2.98B
Weighted Avg Shares (Diluted)39.13M46.37M74.79M107.55M2.98B

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.